BAFF‑R CAR T‑cell treatment for refractory neuroimmune diseases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a phase Ib/IIa open‑label, dose‑escalation and expansion trial administering autologous T cells engineered to express a CAR targeting the BAFF receptor. In Phase I three escalating dose levels will be given to establish the maximum tolerated dose, with about 12 patients per disease cohort; Phase II will expand each disease cohort to about 15 patients at the selected dose to characterize efficacy. Primary assessments include safety and tolerability in the first 4 weeks and recurrence rate at 52 weeks, with secondary measures of CAR T cell expansion, B cell/ASC depletion, disease scores, MRI lesion counts where applicable, and antibody titers. All treatment and follow‑up visits are conducted at the single trial site with serial blood and, when indicated, CSF or bone marrow sampling for pharmacodynamic analyses.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1\. Assessed by the investigator as having a refractory neuroimmune disease;

Refractory neuroimmune diseases were defined as:

1. Poor symptom control on at least three immunosuppressive agents for more than one year;
2. Clinical evidence of at least two relapses within 12 months or three relapses within 24 months and one relapse within 12 months prior to screening.

2\. Male study participants must agree to use contraception during the treatment period for 1 year after receiving study treatment, and sperm donation is prohibited throughout the study period;

3\. In the case of females with childbearing potential, need to agree to use contraception during the treatment period and for at least 1 year after receiving study treatment. Participants must have a negative serum pregnancy test result at screening and a confirmed negative urine pregnancy test result prior to first CART treatment.

Exclusion Criteria:

1. Any medical or psychiatric condition that, in the opinion of the investigator, may jeopardize the study participant or affect the study participant's ability to participate in this study;
2. A history of drug or alcohol abuse within the 12 months prior to baseline, or any condition that in the opinion of the investigator is associated with poor adherence;
3. Women who are breastfeeding or pregnant, or who plan to become pregnant at any time during the 12-month time period following treatment with CART, or a history of spontaneous or induced abortion within 4 weeks prior to screening;
4. Study participants with a clinically relevant active infection (e.g., sepsis, pneumonia, or abscess) or serious infection (resulting in hospitalization or requiring antibiotic therapy) within 4 weeks prior to baseline;
5. The study participant has received a live attenuated vaccination within 8 weeks prior to baseline; or is scheduled to receive a live vaccination (including COVID-19 vaccine) within 8 weeks after treatment;
6. Study participants who have received prior treatment with rituximab within 6 months prior to baseline;
7. Study participants had received tolizumab, eculizumab within 3 months prior to baseline;
8. Study participants who have received intravenous human immunoglobulin, plasma exchange, undergone immunotherapy within 4 weeks prior to baseline;
9. Known concomitant serious underlying diseases, such as hepatic and renal impairment, hematologic disorders, previous severe cardiovascular disease, severe hypertension, diabetes mellitus, poor control of blood pressure and blood glucose;
10. Comorbid mental illness, suicidal ideation (affirmative answer (yes) to question 4 or question 5 of the Colombian Suicide Severity Rating Scale (C-SSRS) indicating a suicide attempt within the last 6 months);
11. Any of the following laboratory abnormalities during the screening period (a repeat measurement may be taken during the screening period prior to randomization to confirm results); (1) Elevated liver enzymes: aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 3 times the upper limit of normal (ULN); (2) Total bilirubin \> 1.5 times the ULN; (3) Estimated glomerular filtration rate (eGFR) \<45 mL/min/1.73 m2; (4) CD19 + B cell count \<40 cells/µL;
12. Presence of a history of tuberculosis infection, high risk of acquired tuberculosis infection;
13. known immunodeficiency diseases, including human immunodeficiency virus (HIV) infection;
14. Viral hepatitis B surface antigen (HBsAg) positivity during the screening period;
15. Receiving blood transfusion therapy 4 weeks prior to baseline or during the screening period;
16. Any other condition that the investigator deems inappropriate for participation in the study.

Where it's running

• Tianjin Medical University General Hospital
  Tianjin, Tianjin Municipality, China Recruiting

Study contacts

• Principal investigator: Qiang Liu, M.D.,Ph.D — Tianjin Medical University General Hospital
• Study coordinator: Qiang Liu, M.D.,Ph.D
• Email: qliu@tmu.edu.cn
• Phone: +86 15022439149

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Identifying biomarkers for autoimmune diseases affecting the nervous system

  This study is trying to find specific markers in the blood of people with autoimmune diseases affecting the nervous system, like Multiple Sclerosis, to help with early diagnosis and better treatment options.

  Recruiting Tongji Hospital · Wuhan · NCT06502015

• Using CT103A cells to treat autoimmune diseases of the nervous system

  This study is testing if a new treatment using CT103A cells can help people with certain autoimmune diseases affecting the nervous system feel better.

  Recruiting Early Phase 1 Tongji Hospital · Wuhan, Hubei · NCT04561557

• Universal CD19/BCMA CAR T-cell therapy for relapsed or refractory neurological autoimmune diseases

  This will test whether a single infusion of universal CD19/BCMA CAR T-cells given after chemotherapy helps adults with relapsed or refractory neurological autoimmune diseases who have CD19- or BCMA-positive B cells.

  Recruiting Early Phase 1 Tianjin Huanhu Hospital · Tianjin · NCT06939166

• Isometric wall squat exercise to lower blood pressure in adults with hypertension

  We’re testing whether doing isometric wall squats at home for 12 weeks can help lower 24-hour blood pressure in adults with essential hypertension.

  Recruiting Korea University Guro Hospital · Seoul, Seoul · NCT07868822

• MG patient registry to track long-term experiences and treatment patterns

  This registry collects information from adults with myasthenia gravis to see how symptoms and quality of life change over time and how treatments relate to those changes.

  Recruiting Autoimmune Neurology Alliance · Framingham, Massachusetts · NCT07761026

• Ublituximab maintenance after efgartigimod response in myasthenia gravis

  This study tests whether giving ublituximab as maintenance after a positive response to efgartigimod helps adults with myasthenia gravis.

  Recruiting at 7 sites Phase 2 TG Therapeutics, Inc. · Colorado Springs, Colorado and 6 other locations · NCT07673744

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.